Biohaven Pharm (BHVN) Receives News Sentiment Score of 0.08
Media coverage about Biohaven Pharm (NYSE:BHVN) has been trending somewhat positive on Thursday, according to Accern Sentiment Analysis. The research firm scores the sentiment of media coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Biohaven Pharm earned a daily sentiment score of 0.08 on Accern’s scale. Accern also gave headlines about the company an impact score of 43.8885451017157 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Here are some of the news headlines that may have impacted Accern’s analysis:
- Biohaven Receives Agreement From FDA on Initial Pediatric Study Plan for Rimegepant, a Second Generation Oral CGRP-Receptor Antagonist for the Acute Treatment of Migraine (finance.yahoo.com)
- Featured Company News – Biohaven Pharma Completed Enrollment in First of Two Pivotal Phase-3 Clinical Trials of Rimegepant for Acute Treatment of Migraine (finance.yahoo.com)
- BRIEF-Biohaven receives agreement from FDA on initial pediatric study plan for rimegepant (feeds.reuters.com)
- William Blair Research Analysts Lift Earnings Estimates for Biohaven Pharm (BHVN) (americanbankingnews.com)
BHVN has been the subject of several research analyst reports. Morgan Stanley raised their target price on shares of Biohaven Pharm from $28.00 to $47.00 and gave the company an “overweight” rating in a research note on Monday, September 25th. Zacks Investment Research raised shares of Biohaven Pharm from a “sell” rating to a “hold” rating in a research note on Friday, September 8th. Piper Jaffray Companies reissued a “buy” rating and issued a $54.00 price objective on shares of Biohaven Pharm in a research note on Tuesday, September 12th. BidaskClub cut shares of Biohaven Pharm from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, September 20th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $43.00 price objective (up from $30.00) on shares of Biohaven Pharm in a research note on Wednesday, September 13th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company. The company has an average rating of “Buy” and an average price target of $40.80.
Shares of Biohaven Pharm (NYSE:BHVN) opened at $25.51 on Thursday. Biohaven Pharm has a twelve month low of $17.00 and a twelve month high of $39.51.
In related news, CFO James Engelhart sold 30,538 shares of Biohaven Pharm stock in a transaction dated Friday, November 10th. The shares were sold at an average price of $26.58, for a total transaction of $811,700.04. Following the completion of the sale, the chief financial officer now owns 25,176 shares in the company, valued at approximately $669,178.08. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Robert Berman sold 27,423 shares of Biohaven Pharm stock in a transaction dated Thursday, November 9th. The shares were sold at an average price of $26.60, for a total transaction of $729,451.80. The disclosure for this sale can be found here. Insiders sold a total of 402,961 shares of company stock valued at $11,098,152 in the last 90 days.
COPYRIGHT VIOLATION WARNING: “Biohaven Pharm (BHVN) Receives News Sentiment Score of 0.08” was originally reported by Watch List News and is owned by of Watch List News. If you are reading this report on another domain, it was stolen and republished in violation of U.S. and international copyright & trademark law. The original version of this report can be accessed at https://www.watchlistnews.com/biohaven-pharm-bhvn-receives-news-sentiment-score-of-0-08/1720810.html.
Biohaven Pharm Company Profile
Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates.
Receive News & Ratings for Biohaven Pharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharm and related companies with Analyst Ratings Network's FREE daily email newsletter.